Skip to main content
S&P 5007,616.46+0.41%DOW52,090.800.00%NASDAQ26,184.39+0.78%BTC$75,720.00-0.87%ETH$2,392.07-1.44%GOLD$4,389.60+1.31%OIL$102.35-3.29%
Smart Investors Daily
KU

NASDAQ · KURA

Kura Oncology, Inc.

Healthcare · Biotechnology

$11.30

Up+$0.08 (+0.74%)

Updated Sep 16, 2026, 3:25 PM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
911.06M
P/E ratio
-4.23
Dividend yield
0.00%
52-week range
$7.54 – $13.90
Volume
1.83M
Avg. volume
1.89M

Price performance

KURA price history

1M range · 20 trading sessions · Daily adjusted prices

KURA closed at $11.30 after 20 trading sessions, down 8.35% for the selected period.

Last close
$11.30
Period change
-8.35%
Period low
$11.30
Period high
$13.59
Daily close
View OHLC price history
KURA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$11.48$11.48$11.025$11.301.83M
Sep 14, 2026$11.37$11.68$11.25$11.561.46M
Sep 11, 2026$11.58$11.75$11.335$11.392.12M
Sep 10, 2026$12.00$12.00$11.4409$11.571.81M
Sep 9, 2026$12.50$12.6063$11.99$12.092.21M
Sep 8, 2026$12.925$12.925$12.50$12.521.51M
Sep 4, 2026$12.94$13.27$12.89$13.251.31M
Sep 3, 2026$13.25$13.29$12.8505$13.151.48M
Sep 2, 2026$12.89$13.41$12.665$13.111.88M
Sep 1, 2026$12.54$12.96$12.432$12.891.51M
Aug 31, 2026$12.71$12.76$12.525$12.651.96M
Aug 28, 2026$13.05$13.17$12.61$12.661.81M
Aug 27, 2026$12.98$13.36$12.89$13.182.37M
Aug 26, 2026$13.63$13.66$12.9853$13.062.71M
Aug 25, 2026$13.59$13.90$12.85$13.595.38M
Aug 24, 2026$11.77$12.87$11.43$12.402.7M
Aug 21, 2026$11.78$12.248$11.67$11.892.03M
Aug 20, 2026$12.36$12.50$11.65$11.712.13M
Aug 19, 2026$12.74$12.90$12.43$12.534.08M
Aug 18, 2026$11.985$12.845$11.985$12.334.09M

Latest KURA news

The latest Smart Investors Daily articles mentioning KURA.

Stock researchCompany · Overview

KURA research

Overview

Company profile and research snapshot.

Company profile

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$35.33
Implied upside
—
Analysts
—
KURA recent ratings
DateFirmRatingTarget
Aug 24, 2026CitizensMarket Outperform—
Aug 13, 2026WedbushOutperform—
Jul 28, 2026WedbushOutperform—
Jun 15, 2026CitizensMarket Outperform—
Apr 14, 2026Lake StreetBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary

Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors. The stated goal is to advance the company’s work in meni

Yahoo · Sep 9, 2026

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres

Yahoo · Sep 8, 2026

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Ms. Fulk will join Kura’s senior leade

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By